106 related articles for article (PubMed ID: 16360198)
1. HMG-CoA reductase inhibitors may affect thrombin generation by reducing factor VII activity in hyperlipidemic patients.
Ural AU; Avcu F
Thromb Res; 2006; 118(5):665-6. PubMed ID: 16360198
[No Abstract] [Full Text] [Related]
2. Atorvastatin reduces thrombin generation after percutaneous coronary intervention independent of soluble tissue factor.
Bartok A; Steiner S; Seidinger D; Jetzl A; Huber K; Minar E; Stefenelli T; Kopp CW
Thromb Res; 2005; 115(6):469-74. PubMed ID: 15792677
[TBL] [Abstract][Full Text] [Related]
3. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients.
Sanguigni V; Pignatelli P; Lenti L; Ferro D; Bellia A; Carnevale R; Tesauro M; Sorge R; Lauro R; Violi F
Circulation; 2005 Feb; 111(4):412-9. PubMed ID: 15687128
[TBL] [Abstract][Full Text] [Related]
4. High doses of atorvastatin do not affect activity of prothrombinase in patients with acute coronary syndromes.
Olivotti L; Ghigliotti G; Spallarossa P; Leslie S; Rossettin P; Barsotti A; Brunelli C
Blood Coagul Fibrinolysis; 2002 Jun; 13(4):315-22. PubMed ID: 12032397
[TBL] [Abstract][Full Text] [Related]
5. HMG-CoA reductase inhibitors and renal function.
Campese VM; Park J
Clin J Am Soc Nephrol; 2007 Nov; 2(6):1100-3. PubMed ID: 17942762
[No Abstract] [Full Text] [Related]
6. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study.
Okazaki S; Yokoyama T; Miyauchi K; Shimada K; Kurata T; Sato H; Daida H
Circulation; 2004 Aug; 110(9):1061-8. PubMed ID: 15326073
[TBL] [Abstract][Full Text] [Related]
7. High-dose atorvastatin in acute coronary and cerebrovascular syndromes.
Lavie CJ; Milani RV
JACC Cardiovasc Interv; 2010 Mar; 3(3):340-2. PubMed ID: 20298995
[No Abstract] [Full Text] [Related]
8. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease.
Bloom JM
N Engl J Med; 1999 Dec; 341(24):1854-5. PubMed ID: 10610466
[No Abstract] [Full Text] [Related]
9. [AVERT [The Atorvastatin versus Revascularization Treatment]].
Mokuno H
Nihon Rinsho; 2001 Mar; 59 Suppl 3():436-41. PubMed ID: 11347110
[No Abstract] [Full Text] [Related]
10. Intensive lipid lowering with atorvastatin in coronary disease.
Southern W
N Engl J Med; 2005 Jul; 353(1):93-6; author reply 93-6. PubMed ID: 16003831
[No Abstract] [Full Text] [Related]
11. Atorvastatin and fibrinogen--a small subgroup shows extreme response.
Sinzinger H; Rodrigues M
Atherosclerosis; 1999 Aug; 145(2):415-7. PubMed ID: 10488971
[No Abstract] [Full Text] [Related]
12. Atorvastatin does not alter the anticoagulant activity of warfarin.
Stern R; Abel R; Gibson GL; Besserer J
J Clin Pharmacol; 1997 Nov; 37(11):1062-4. PubMed ID: 9506000
[TBL] [Abstract][Full Text] [Related]
13. Aggressive low-density lipoprotein cholesterol lowering in secondary prevention of coronary heart disease.
Clearfield M
Curr Atheroscler Rep; 2006 Jan; 8(1):7-8. PubMed ID: 16455005
[No Abstract] [Full Text] [Related]
14. [The use of atorvastatin in patients with rheumatoid arthritis with hyperlipidemia].
Nikitina NM; Rebrov AP
Kardiologiia; 2009; 49(9):21-6. PubMed ID: 19772499
[TBL] [Abstract][Full Text] [Related]
15. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
Malhotra HS; Goa KL
Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
[TBL] [Abstract][Full Text] [Related]
16. Effects of atorvastatin on serum lipids, lipoproteins, and hemostasis.
Kushiya F; Wada H; Ooi K; Sakurai Y; Sakaguchi A; Noda M; Abe Y; Nakasaki T; Tsukada T; Shiku H; Nobori T
Am J Hematol; 2005 Jan; 78(1):1-6. PubMed ID: 15609278
[TBL] [Abstract][Full Text] [Related]
17. HMG CoA reductase inhibition and endothelial function in children with chronic kidney disease (CKD)--a pilot study.
Mackie FE; Rosenberg AR; Harmer JA; Kainer G; Celermajer DS
Acta Paediatr; 2010 Mar; 99(3):457-9. PubMed ID: 20050832
[No Abstract] [Full Text] [Related]
18. [Atorvastatin in treatment of patients with coronary heart disease and dislipidemiya and high general risk: efficiency and safety estimation. Design and main results of ATLANTIKA].
Mareev VIu; Belenkov IuN; Oganov RG; Barbik-Zhagar B
Kardiologiia; 2008; 48(11):4-13. PubMed ID: 19076074
[No Abstract] [Full Text] [Related]
19. Effects of statins (atorvastatin) on serum lipoprotein levels in patients with primary hyperlipidemia and coronary heart disease.
Jurukovska-Nospal M; Arsova V; Levchanska J; Sidovska-Ivanovska B
Prilozi; 2007 Dec; 28(2):137-48. PubMed ID: 18356785
[TBL] [Abstract][Full Text] [Related]
20. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.
Mitsios JV; Papathanasiou AI; Rodis FI; Elisaf M; Goudevenos JA; Tselepis AD
Circulation; 2004 Mar; 109(11):1335-8. PubMed ID: 15023882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
